THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET SIZE IS EXPECTED TO REACH USD 5.6 BILLION BY 2027, OBSERVING A GROWTH RATE OF 4% BY 2026-2027.

The Global Viral Transport Medium Market Size, Share, Growth, And Trends Analysis Report By

  • Products: Viral Transport Media, Universal Transport Media, and Molecular Transport Media
  • Usage: Diagnosis and Pre-Clinical Testing
  • Indication: Influenza & Covid, Herpes Simplex Virus, Respiratory Syncytial Virus, Varicella-Zoster Virus, and Others
  • End-User: Diagnostic Labs, Hospitals & Clinics, and Others
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2022–2027.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

274 Pages

icon-table

157 Tables

icon-chart

111 Charts

icon-region

5 Regions

icon-country

18 Countries

icon-company

45 Companies

icon-market

5 Market Segment

GLOBAL VIRAL TRANSPORT MEDIUM MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 5.6 billion
CAGR (2022-2027) (3.51%)
Base Year 2021
Forecast Year 2022-2027
Market Segments Product, Usage, Indication, End-User, and Geography
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, UK, France, Italy, Germany, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, and South Africa

MARKET ANALYSIS

The viral transport medium market is expected to grow at a CAGR of 4% from 2026 to 2027 and is projected to reach $5 billion in 2027. The sudden onset of the COVID-19 pandemic significantly changed the demand for transport medium products and related kits. With the fast spread of the COVID-19 virus, many countries prioritized diagnostic testing for quick diagnosis of the virus. This fuelled the exponential increase in demand for VTM kits for sample collection from suspected COVID-19 patients. Owing to the surge in demand for diagnostic tests and sample collection from people, many vendors increased their production. They continuously tried to deliver many viral transport media kits to meet the exponential demand for COVID-19 diagnostic tests. In March 2020, increased demand for covid-19 testing led to a global shortage of nasopharyngeal swabs and viral transport medium test kits that significantly impacted large-scale testing efforts.

WHAT IS A VIRAL TRANSPORT MEDIUM?

Viral transport media are the medical kits, swabs, and tubes used to collect, preserve, and transport viral specimens for research and diagnostic tests, which exist in several formulations, consisting of a buffered salt solution, a complex source of protein and amino acids, and anti-microbial agents. It preserves viruses and is either used for amplification by nucleic acid amplification testing (NAAT) technology or viral culture. It allows research collection, preservation, and transportation of viral specimens, including conventional cell culture methods, molecular biology techniques, and diagnostic tests. The importance of viral transport medium was known globally when a new H1N1 influenza virus was identified, causing the world's first flu pandemic in more than 40 years. Since then, it has been used majorly by hospitals, labs, and academic/research institutes for transporting viral samples across the research and clinical value chain. During the transport, the virus, if present, in the sample specimen should remain intact until the testing is completed.

Suddenly increased SARS-COV-2 infection rate drive substantial demand for VTM kits. It resulted in increased manufacturing and manufacturing capacity of the vendors. Most of the leading and emerging companies fulfilled the supply across the healthcare system in the world. In 2020, Thermo Fisher Scientific, one of the leading suppliers of viral transport kits, invested around $40 million in Lenexa and Kansas manufacturing facilities to scale up the production of the kits.

The pandemic increased the manufacturing of VTM kits globally and gave emerging market players new opportunities. Several new entries and new products were launched in the same period. Most of the global market players looked for a maximum supply of these kits; on the other side, newcomers entered with new products.

  • In June 2020, India-based IIT Guwahati developed a new product. The SPLID Kit is a unique and world-class affordable solution which are the first-stop source helped in the collection of oral and nasal swabs specimen.
  • In 2021, the leading manufacturing company of viral transport media, Vircell, launched a new VTM kit solution. This product is validated for collecting and preserving viruses such as SARS-COV-2 & influenza A virus.
  • The UK-based company EKF Diagnostics launched a new molecular transport media product for influenza and Covid-19 virus collection. It is one of the unique products that novel transport molecular media used for dual purposes such as covid-19 and influenza sampling and enabled safe sample handling and testing with one sample swab.

SWAB AND VIRAL TRANSPORT MEDIUM MARKET SCENARIO

Viral transport medium kits are constantly in demand due to the increasing prevalence of infectious diseases. Viral infections are one of the major burdens seen during the pandemic period. The rising prevalence of viral infectious diseases enabled the growth of viral transport media kits. Some of the viral infectious diseases are Covid-19, influenza virus, enterovirus D68, herpes, varicella, RSV, etc. In diagnosing the diseases mentioned above, collection of samples, preservation, and transportation are required, whereas VTM kits are practitioners' most prominently used solutions. According to the Plos One article 2021, based on studies documented from 2007 to 2020, the overall prevalence of respiratory syncytial virus was around 11%, and adenovirus accounted for 13%. Influenza viral infection accounts high burden worldwide, which requires diagnosis and testing.

Non-polio enterovirus causes around 10-15 million infection cases annually & on the other side, 10,000 hospitalizations each year in the US. On the other side, herpes is one of the severe viral infectious conditions that demand laboratory testing for diagnosis and cure. It is categorized into the herpes simplex virus type 1 and herpes simplex virus type 2. It is a sexually transmitted infection that is present lifelong. Around 3.7 billion people under 50 suffer from HSV-1 and 491 million from HSV-2 under the age of 15–49-year-old.

Conversely, increasing the diagnosis rate for viral infectious diseases constantly drives the market growth. The increasing diagnosis rate of viral diseases requires laboratory testing of clinical specimens to identify the virus, viral antigens, and antibodies. In the last form, two decades major revolution was addressed in virus diagnostic laboratories. Also, the rapid increase in the aging population, the rise in the number of people undergoing various voluntary surgeries, and other factors have accelerated the requirement for various diagnostic tests that involve VTM kits. With the rising prevalence of various acute and chronic diseases worldwide, the number of surgeries performed to treat such diseases is also increasing rapidly.

A surge in Mass Testing for COVID-19 & Influenza

The demand for viral transport has increased exponentially during the COVID-19 pandemic. With academic/research institutes intensifying their experiments for developing vaccines and mass testing to stop the spread of COVID-19 globally, vendors have increased their manufacturing capacities and produced billions of VTM kits. Companies focus on innovation and developing kits containing double-ended flocked swabs, vials, antibiotics, and other items that inhibit microbial contamination. In addition, with the continuous increase of seasonal flu cases, manufacturers are also manufacturing viral transport for influenza tests, owing to influenza-related morbidity and mortality in many countries.

MARKET SIZE ANALYSIS BY PRODUCT, USAGE, INDICATION, AND END-USERS

In 2021, the viral transport media segment accounted for a revenue share of 46% in the global viral transport medium market and dominated other segments. The universal transport media segment accounted for 34%, and the molecular transport media segment accounted for 20% market share in 2021. Molecular transport media experienced high demand during the SARS-COV-2 pandemic. It is used to collect samples of SARS-COV-2, HIV, RSV, influenza, and TB. 

The rising diagnosis rate of covid-19 cases drives significant market growth by diagnosing severe SARS-COV-2 infection. In 2021, the diagnosis segment accounted for a revenue share of 67.44% in the global viral transport media market and showed dominance over the pre-clinical testing segment.

Influenza is one of the most common viral infections globally. In the global Viral Transport Medium Market, influenza & covid-19 indication segment accounted for 73.09% market share in 2021. The higher infection rate of Covid-19 across the world dominated the market with a higher market share.

In 2021, the lab's segment accounted for a revenue share of 40.30% in the global viral transport media market and dominated to other two segments. An increasing number of microbiology labs, research labs, biotech labs, and pharmaceutical and biotech company/ organizational labs drive viral transport kits' adoption and contribute to the market growth with dominance over other segments.

GEOGRAPHY INSIGHTS

The market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa region. In North America, a high number of laboratory tests were registered during the pandemic, fueling market growth. On the other side, the presence of biopharma companies, a high number of labs, well-developed healthcare services, and research studies on viral infection drives significant market growth in the region and accounted 33.18% higher market share. Apart from the Covid-19 pandemic burden, other viral infections such as influenza, herpes, varicella, respiratory syncytial virus, and other viral infectious diseases demand the diagnosis where VTM kits play a vital role in the collection, preservation, and transportation of specimens. The rising prevalence of viral infection worldwide delivers high demand for VTM kits. Influenza viral infections continue to increase in African, North America, and Asia Pacific regions.

COMPETITIVE LANDSCAPE

The global viral transport medium market is highly competitive in nature due to the presence of domestic, regional, and international market players. Also, the geographical presence of key market players and their broad distribution channels increases market competitiveness through their major supply, import, and export strategies. The outbreak of the COVID-19 pandemic significantly increased demand for VTM kits, driving high export and import of VTM kits from different countries through major market players. Vendors are increasing efforts to manufacture VTM products as per regulatory bodies' requirements. For instance, Hardy Diagnostics, an FDA-licensed manufacturer of medical devices for microbiological testing, launched the Universal Transport Medium, which is suitable for the collection, maintenance, and long-term freeze storage of clinical specimens. Apart from hospital and retail pharmacies, vendors also offer huge volumes of orders from online pharmacies. Hence, they collaborate with e-commerce companies to increase their sales and revenue options.

Puritan Medical Products, Thermo Fisher Scientific, BD (Becton Dickinson), Laboratory Corporation of America, Hardy Diagnostics, Vircell, and Himedia Laboratories are some of the leading market players engaged in the manufacturing and supplying VTM kits in the global viral transport medium market. Many new, local, and regional players have increased market competitiveness.

Frequently Asked Questions

HOW BIG IS THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?

The global viral transport medium market is expected to reach USD 5.6 billion by 2027.

WHO ARE THE MAJOR PLAYERS IN THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?

BD (Beckton Dickinson), Hardy Diagnostics, HiMedia Laboratories, Laboratory Corporation of America, Puritan Medical Products, Thermo Fisher Scientific, and Vircell.

WHAT ARE THE GROWTH FACTORS IN THE GLOBAL VIRAL TRANSPORT MEDIUM MARKET?

Increasing prevalence of infectious disease, diagnosis rates for viral infectious diseases, and a surge in covid-19 infections are the major growth factors in the global viral transport medium market.

WHAT ARE SOME OF THE LATEST TRENDS THAT WILL SHAPE THE FUTURE OF THE GLOBAL VTM MARKET?

Launches of new products and entry of new market players are the latest trends shaping the future of the global VTM market.

WHICH REGION IS EXPECTED TO OBSERVE THE LARGEST SHARE IN THE VIRAL TRANSPORT MEDIUM MARKET?

North America holds the largest share in the VTM market.

Download Free Sample

The global viral transport medium market is expected to reach USD 5.6 billion by 2027, observing a growth rate of 4% by 2026-2027.

The following factors driving the market growth are:

  • Increasing Prevalence of Infectious Diseases
  • A surge in COVID-19 Infections
  • Increase in Diagnosis Rates for Viral Infectious Diseases

Base Year: 2021

Forecast Year: 2022-2027

Key Vendors

  • BD (Beckton Dickinson)
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Hardy Diagnostics
  • HiMedia Laboratories
  • Laboratory Corporation of America
  • Puritan Medical Products
  • Thermo Fisher Scientific
  • Vircell

Other Prominent Vendors

  • AB Medical
    • Business Overview
    • Product Offerings
  • AccuGene USA
  • Apical Scientific
  • Azooka Labs
  • Biomed Diagnostics
  • bioBoaVista
  • Biogenex Laboratories
  • Biologix Group
  • Biocomma
  • Charm Sciences
  • Creative Life Sciences Co. Ltd
  • Citotest Labware Manufacturing
  • CPT Medical
  • Copan Diagnostic Inc.
  • Diasorin Molecular
  • EKF Diagnostic
  • Ensol Biosciences
  • Gemini Bioproducts
  • General Biologics
  • Gentueri
  • Genesis Lifetech Marketing
  • Han Chang Medic
  • Hebei Chaoran Medical Instruments
  • KSL Diagnostics
  • Lucence Health
  • LaunchWorks
  • Liofilchem
  • Medical Wire & Equipment
  • Miraclean Technology (Mantacc)
  • MetaDesign Solutions
  • Manila HealthTek
  • MatTek
  • Nodford International
  • Starplex Scientific
  • Sansure Biotech
  • Titan Biotech
  • Vegas Biotech
  • Zybio

Segmentation by Products

  • Viral Transport Media
  • Universal Transport Media
  • Molecular Transport Media

Segmentation by Usage

  • Diagnosis
  • Pre-Clinical Testing

Segmentation by Indication

  • Influenza & Covid
  • Herpes Simplex Virus
  • Respiratory Syncytial Virus
  • Varicella Zoster Virus
  • Others

Segmentation by End-User

  • Diagnostic Labs
  • Hospitals & Clinics
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • UK
    • France
    • Italy
    • Germany
    • Spain
  • APAC
    • China
    • Japan
    • India
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW

8 MARKET OPPORTUNITIES & TRENDS

8.1 INCREASING DEMAND FOR VTM DUE TO SURGE IN COVID-19 INFECTION

8.2 LAUNCH OF NEW PRODUCTS AND ENTRY OF NEW MARKET PLAYERS

9 MARKET GROWTH ENABLERS

9.1 INCREASING PREVALENCE OF VIRAL INFECTIOUS DISEASES

9.2 SURGE IN COVID-19 INFECTIONS

9.3 INCREASE IN DIAGNOSIS OF VIRAL INFECTIOUS DISEASES

10 MARKET RESTRAINTS

10.1 VTM SPECIMENS POSE HIGHER BIOHAZARD DURING TRANSPORTATION THAN OTHER SOLUTIONS

10.2 FALSE-NEGATIVE RESULTS IN BORDERLINE CASES

10.3 LACK OF ACCESS TO DIAGNOSIS SERVICES IN LMICS

11 MARKET LANDSCAPE

11.1 MARKET OVERVIEW

11.2 MARKET SIZE & FORECAST

11.3 FIVE FORCES ANALYSIS

11.3.1 THREAT OF NEW ENTRANTS

11.3.2 BARGAINING POWER OF SUPPLIERS

11.3.3 BARGAINING POWER OF BUYERS

11.3.4 THREAT OF SUBSTITUTES

11.3.5 COMPETITIVE RIVALRY

12 PRODUCTS

12.1 MARKET SNAPSHOT & GROWTH ENGINE

12.2 MARKET OVERVIEW

12.3 VIRAL TRANSPORT MEDIA

12.3.1 MARKET OVERVIEW

12.3.2 MARKET SIZE & FORECAST

12.3.3 MARKET BY GEOGRAPHY

12.4 UNIVERSAL TRANSPORT MEDIA

12.4.1 MARKET OVERVIEW

12.4.2 MARKET SIZE & FORECAST

12.4.3 MARKET BY GEOGRAPHY

12.5 MOLECULAR TRANSPORT MEDIA

12.5.1 MARKET OVERVIEW

12.5.2 MARKET SIZE & FORECAST

12.5.3 MARKET BY GEOGRAPHY

13 USAGE

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 DIAGNOSIS

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 MARKET BY GEOGRAPHY

13.4 PRE-CLINICAL TESTING

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 MARKET BY GEOGRAPHY

14 INDICATION

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.3 INFLUENZA & COVID-19

14.3.1 MARKET OVERVIEW

14.3.2 MARKET SIZE & FORECAST

14.3.3 MARKET BY GEOGRAPHY

14.4 HERPES SIMPLEX VIRUS

14.4.1 MARKET OVERVIEW

14.4.2 MARKET SIZE & FORECAST

14.4.3 MARKET BY GEOGRAPHY

14.5 RESPIRATORY SYNCYTIAL VIRUS (RSV)

14.5.1 MARKET OVERVIEW

14.5.2 MARKET SIZE & FORECAST

14.5.3 MARKET BY GEOGRAPHY

14.6 VARICELLA-ZOSTER

14.6.1 MARKET OVERVIEW

14.6.2 MARKET SIZE & FORECAST

14.6.3 MARKET BY GEOGRAPHY

14.7 OTHERS

14.7.1 MARKET OVERVIEW

14.7.2 MARKET SIZE & FORECAST

14.7.3 MARKET BY GEOGRAPHY

15 END-USER

15.1 MARKET SNAPSHOT & GROWTH ENGINE

15.2 MARKET OVERVIEW

15.3 LABS

15.3.1 MARKET OVERVIEW

15.3.2 MARKET SIZE & FORECAST

15.3.3 MARKET BY GEOGRAPHY

15.4 HOSPITALS & CLINICS

15.4.1 MARKET OVERVIEW

15.4.2 MARKET SIZE & FORECAST

15.4.3 MARKET BY GEOGRAPHY

15.5 OTHERS

15.5.1 MARKET OVERVIEW

15.5.2 MARKET SIZE & FORECAST

15.5.3 MARKET BY GEOGRAPHY

16 GEOGRAPHY

16.1 MARKET SNAPSHOT & GROWTH ENGINE

16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

17.1 MARKET OVERVIEW

17.2 MARKET SIZE & FORECAST

17.3 PRODUCT

17.3.1 MARKET SIZE & FORECAST

17.4 USAGE

17.4.1 MARKET SIZE & FORECAST

17.5 INDICATION

17.5.1 MARKET SIZE & FORECAST

17.6 END-USER

17.6.1 MARKET SIZE & FORECAST

17.7 KEY COUNTRIES

17.7.1 US: MARKET SIZE & FORECAST

17.7.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

18.1 MARKET OVERVIEW

18.2 MARKET SIZE & FORECAST

18.3 PRODUCT

18.3.1 MARKET SIZE & FORECAST

18.4 USAGE

18.4.1 MARKET SIZE & FORECAST

18.5 INDICATION

18.5.1 MARKET SIZE & FORECAST

18.6 END-USER

18.6.1 MARKET SIZE & FORECAST

18.7 KEY COUNTRIES

18.7.1 UK: MARKET SIZE & FORECAST

18.7.2 FRANCE: MARKET SIZE & FORECAST

18.7.3 ITALY: MARKET SIZE & FORECAST

18.7.4 GERMANY: MARKET SIZE & FORECAST

18.7.5 SPAIN: MARKET SIZE & FORECAST

19 APAC

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.3 PRODUCT

19.3.1 MARKET SIZE & FORECAST

19.4 USAGE

19.4.1 MARKET SIZE & FORECAST

19.5 INDICATION

19.5.1 MARKET SIZE & FORECAST

19.6 END-USER

19.6.1 MARKET SIZE & FORECAST

19.7 KEY COUNTRIES

19.7.1 CHINA: MARKET SIZE & FORECAST

19.7.2 JAPAN: MARKET SIZE & FORECAST

19.7.3 INDIA: MARKET SIZE & FORECAST

19.7.4 AUSTRALIA: MARKET SIZE & FORECAST

19.7.5 SOUTH KOREA: MARKET SIZE & FORECAST

20 LATIN AMERICA

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.3 PRODUCT

20.3.1 MARKET SIZE & FORECAST

20.4 USAGE

20.4.1 MARKET SIZE & FORECAST

20.5 INDICATION

20.5.1 MARKET SIZE & FORECAST

20.6 END-USER

20.6.1 MARKET SIZE & FORECAST

20.7 KEY COUNTRIES

20.7.1 BRAZIL: MARKET SIZE & FORECAST

20.7.2 MEXICO: MARKET SIZE & FORECAST

20.7.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

21.1 MARKET OVERVIEW

21.2 MARKET SIZE & FORECAST

21.3 PRODUCT

21.3.1 MARKET SIZE & FORECAST

21.4 USAGE

21.4.1 MARKET SIZE & FORECAST

21.5 INDICATION

21.5.1 MARKET SIZE & FORECAST

21.6 USAGE

21.6.1 MARKET SIZE & FORECAST

21.7 END-USER

21.7.1 MARKET SIZE & FORECAST

21.8 KEY COUNTRIES

21.8.1 TURKEY: MARKET SIZE & FORECAST

21.8.2 SAUDI ARABIA: MARKET SIZE & FORECAST

21.8.3 SOUTH AFRICA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

22.1 COMPETITION OVERVIEW

22.2 MARKET SHARE ANALYSIS

23 KEY COMPANY PROFILES

23.1 BD (BECTON DICKINSON)

23.1.1 BUSINESS OVERVIEW

23.1.2 PRODUCT OFFERINGS

23.1.3 KEY STRATEGIES

23.1.4 KEY STRENGTHS

23.1.5 KEY OPPORTUNITIES

23.2 HARDY DIAGNOSTICS

23.2.1 BUSINESS OVERVIEW

23.2.2 PRODUCT OFFERINGS

23.2.3 KEY STRATEGIES

23.2.4 KEY STRENGTHS

23.2.5 KEY OPPORTUNITIES

23.3 HIMEDIA LABORATORIES

23.3.1 BUSINESS OVERVIEW

23.3.2 PRODUCT OFFERINGS

23.3.3 KEY STRATEGIES

23.3.4 KEY STRENGTHS

23.3.5 KEY OPPORTUNITIES

23.4 LABORATORY CORPORATION OF AMERICA

23.4.1 BUSINESS OVERVIEW

23.4.2 PRODUCT OFFERINGS

23.4.3 KEY STRATEGIES

23.4.4 KEY STRENGTHS

23.4.5 KEY OPPORTUNITIES

23.5 PURITAN MEDICAL PRODUCTS

23.5.1 BUSINESS OVERVIEW

23.5.2 PRODUCT OFFERINGS

23.5.3 KEY STRATEGIES

23.5.4 KEY STRENGTHS

23.5.5 KEY OPPORTUNITIES

23.6 THERMO FISHER SCIENTIFIC

23.6.1 BUSINESS OVERVIEW

23.6.2 PRODUCT OFFERINGS

23.6.3 KEY STRATEGIES

23.6.4 KEY STRENGTHS

23.7 VIRCELL

23.7.1 BUSINESS OVERVIEW

23.7.2 PRODUCT OFFERINGS

23.7.3 KEY STRATEGIES

23.7.4 KEY STRENGTHS

23.7.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

24.1 AB MEDICAL

24.1.1 BUSINESS OVERVIEW

24.1.2 PRODUCT OFFERINGS

24.2 ACCUGENE USA

24.2.1 BUSINESS OVERVIEW

24.2.2 PRODUCT OFFERINGS

24.3 APICAL SCIENTIFIC

24.3.1 BUSINESS OVERVIEW

24.3.2 PRODUCT OFFERING

24.4 AZOOKA LABS

24.4.1 BUSINESS OVERVIEW

24.4.2 PRODUCT OFFERING

24.5 BIOMED DIAGNOSTICS

24.5.1 BUSINESS OVERVIEW

24.5.2 PRODUCT OFFERINGS

24.6 BIOBOAVISTA

24.6.1 BUSINESS OVERVIEW

24.6.2 PRODUCT OFFERINGS

24.7 BIOGENEX LABORATORIES

24.7.1 BUSINESS OVERVIEW

24.7.2 PRODUCT OFFERINGS

24.8 BIOLOGIX GROUP

24.8.1 BUSINESS OVERVIEW

24.8.2 PRODUCT OFFERINGS

24.9 BIOCOMMA

24.9.1 BUSINESS OVERVIEW

24.9.2 PRODUCT OFFERINGS

24.10 CHARM SCIENCES

24.10.1 BUSINESS OVERVIEW

24.10.2 PRODUCT OFFERINGS

24.11 CREATIVE LIFE SCIENCES CO. LTD.

24.11.1 BUSINESS OVERVIEW

24.11.2 PRODUCT OFFERINGS

24.12 CITOTEST LABWARE MANUFACTURING

24.12.1 BUSINESS OVERVIEW

24.12.2 PRODUCT OFFERINGS

24.13 CPT MEDICAL

24.13.1 BUSINESS OVERVIEW

24.13.2 PRODUCT OFFERINGS

24.14 COPAN DIAGNOSTIC INC.

24.14.1 BUSINESS OVERVIEW

24.14.2 PRODUCT OFFERINGS

24.15 DIASORIN MOLECULAR

24.15.1 BUSINESS OVERVIEW

24.15.2 PRODUCT OFFERINGS

24.16 EKF DIAGNOSTICS HOLDINGS PLC

24.16.1 BUSINESS OVERVIEW

24.16.2 PRODUCT OFFERINGS

24.17 ENSOL BIOSCIENCES

24.17.1 BUSINESS OVERVIEW

24.17.2 PRODUCT OFFERINGS

24.18 GEMINI BIOPRODUCTS

24.18.1 BUSINESS OVERVIEW

24.18.2 PRODUCT OFFERINGS

24.19 GENERAL BIOLOGICS

24.19.1 BUSINESS OVERVIEW

24.19.2 PRODUCT OFFERINGS

24.20 GENTUERI

24.20.1 BUSINESS OVERVIEW

24.20.2 PRODUCT OFFERINGS

24.21 GENESIS LIFETECH MARKETING

24.21.1 BUSINESS OVERVIEW

24.21.2 PRODUCT OFFERINGS

24.22 HAN CHANG MEDIC

24.22.1 BUSINESS OVERVIEW

24.22.2 PRODUCT OFFERINGS

24.23 HEBEI CHAORAN MEDICAL INSTRUMENTS

24.23.1 BUSINESS OVERVIEW

24.23.2 PRODUCT OFFERING

24.24 KSL DIAGNOSTICS

24.24.1 BUSINESS OVERVIEW

24.24.2 PRODUCT OFFERING

24.25 LUCENCE HEALTH

24.25.1 BUSINESS OVERVIEW

24.25.2 PRODUCT OFFERINGS

24.26 LAUNCHWORKS

24.26.1 BUSINESS OVERVIEW

24.26.2 PRODUCT OFFERING

24.27 LIOFILCHEM

24.27.1 BUSINESS OVERVIEW

24.27.2 PRODUCT OFFERING

24.28 MEDICAL WIRE & EQUIPMENT (MWE)

24.28.1 BUSINESS OVERVIEW

24.28.2 PRODUCT OFFERINGS

24.29 MIRACLEAN TECHNOLOGY

24.29.1 BUSINESS OVERVIEW

24.29.2 PRODUCT OFFERINGS

24.30 METADESIGN SOLUTIONS

24.30.1 BUSINESS OVERVIEW

24.30.2 PRODUCT OFFERINGS

24.31 MANILA HEALTHTEK

24.31.1 BUSINESS OVERVIEW

24.31.2 PRODUCT OFFERING

24.32 MATTEK

24.32.1 BUSINESS OVERVIEW

24.32.2 PRODUCT OFFERING

24.33 NODFORD INTERNATIONAL

24.33.1 BUSINESS OVERVIEW

24.33.2 PRODUCT OFFERING

24.34 STARPLEX SCIENTIFIC

24.34.1 BUSINESS OVERVIEW

24.34.2 PRODUCT OFFERINGS

24.35 SANSURE BIOTECH

24.35.1 BUSINESS OVERVIEW

24.35.2 PRODUCT OFFERINGS

24.36 TITAN BIOTECH

24.36.1 BUSINESS OVERVIEW

24.36.2 PRODUCT OFFERINGS

24.37 VEGAS BIOTECH

24.37.1 BUSINESS OVERVIEW

24.37.2 PRODUCT OFFERING

24.38 ZYBIO

24.38.1 BUSINESS OVERVIEW

24.38.2 PRODUCT OFFERING

25 REPORT SUMMARY

25.1 KEY TAKEAWAYS

25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

26.1 MARKET BY GEOGRAPHY

26.2 MARKET BY PRODUCT

26.3 MARKET BY USAGE

26.4 MARKET BY INDICATION

26.5 MARKET BY END-USER

26.6 PRODUCT: MARKET BY GEOGRAPHY

26.6.1 VIRAL TRANSPORT MEDIA: MARKET BY GEOGRAPHY

26.6.2 UNIVERSAL TRANSPORT MEDIA: MARKET BY GEOGRAPHY

26.6.3 MOLECULAR TRANSPORT MEDIA: MARKET BY GEOGRAPHY

26.7 USAGE: MARKET BY GEOGRAPHY

26.7.1 DIAGNOSIS: MARKET BY GEOGRAPHY

26.7.2 PRE-CLINICAL TESTING: MARKET BY GEOGRAPHY

26.8 INDICATION: MARKET BY GEOGRAPHY

26.8.1 INFLUENZA & COVID-19: MARKET BY GEOGRAPHY

26.8.2 HERPES: MARKET BY GEOGRAPHY

26.8.3 RESPIRATORY SYNCYTIAL VIRUS: MARKET BY GEOGRAPHY

26.8.4 VARICELLA ZOSTER VIRUS: MARKET BY GEOGRAPHY

26.8.5 OTHER INDICATIONS: MARKET BY GEOGRAPHY

26.9 END-USER: MARKET BY GEOGRAPHY

26.9.1 LABS: MARKET BY GEOGRAPHY

26.9.2 HOSPITALS & CLINICS: MARKET BY GEOGRAPHY

26.9.3 OTHER INDICATION: MARKET BY GEOGRAPHY

27 APPENDIX

27.1 ABBREVIATIONS

LIST OF EXHIBITS

EXHIBIT 1 SEGMENTATION OF GLOBAL VIRAL TRANSPORT MEDIUM MARKET

EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021

EXHIBIT 3 INCREASING DEMAND FOR VTM DUE TO SURGE IN COVID-19 INFECTION

EXHIBIT 4 IMPACT OF LAUNCHES OF NEW PRODUCTS AND ENTRY OF NEW MARKET PLAYERS

EXHIBIT 5 IMPACT OF INCREASING PREVALENCE OF INFECTIOUS DISEASES

EXHIBIT 6 IMPACT OF SURGE IN COVID-19 INFECTIONS

EXHIBIT 7 DAILY CORONAVIRUS CASES 2020-2022 (MILLION)

EXHIBIT 8 COVID-19 TEST PER MILLION CASES IN FEB 2022

EXHIBIT 9 IMPACT OF INCREASE IN DIAGNOSIS RATES FOR VIRAL INFECTIOUS DISEASES

EXHIBIT 10 IMPACT OF VTM SPECIMENS POSE HIGHER BIOHAZARD DURING TRANSPORTATION THAN OTHER SOLUTIONS

EXHIBIT 11 IMPACT OF FALSE-NEGATIVE RESULTS IN BORDERLINE CASES

EXHIBIT 12 VIRAL TRANSPORT MEDIA: FACTORS AFFECTING NEGATIVE/ FALSE RESULT

EXHIBIT 13 IMPACT OF LACK OF ACCESS TO DIAGNOSIS SERVICES IN LMICS

EXHIBIT 14 GLOBAL VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 15 FIVE FORCES ANALYSIS 2021

EXHIBIT 16 INCREMENTAL GROWTH BY PRODUCTS 2021 & 2027

EXHIBIT 17 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2022-2027

EXHIBIT 18 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS: INCREMENTAL GROWTH

EXHIBIT 19 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS: ABSOLUTE GROWTH

EXHIBIT 20 GLOBAL VIRAL TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 21 GLOBAL VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 22 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 23 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET 2021–2027 ($ MILLION)

EXHIBIT 24 GLOBAL TREND IN CASE NOTIFICATION OF PEOPLE NEWLY DIAGNOSED WITH TB 2016-2020 (PER YEAR IN MILLION)

EXHIBIT 25 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 26 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET 2021–2027 ($ MILLION)

EXHIBIT 27 INCREMENTAL GROWTH BY USAGE 2021 & 2027

EXHIBIT 28 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USES 2022-2027

EXHIBIT 29 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE: INCREMENTAL GROWTH

EXHIBIT 30 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE: ABSOLUTE GROWTH

EXHIBIT 31 GLOBAL DIAGNOSIS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 32 GLOBAL PREVALENCE OF STI VIRAL DISEASES 2020 (MILLION)

EXHIBIT 33 GLOBAL DIAGNOSIS USAGE MARKET 2021–2027 ($ MILLION)

EXHIBIT 34 GLOBAL PRE-CLINICAL TESTING MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 35 GLOBAL PRE-CLINICAL TESTING MARKET 2021–2027 ($ MILLION)

EXHIBIT 36 INCREMENTAL GROWTH BY PRODUCTS 2021 & 2027

EXHIBIT 37 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2022-2027

EXHIBIT 38 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION: INCREMENTAL GROWTH

EXHIBIT 39 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION: ABSOLUTE GROWTH

EXHIBIT 41 GLOBAL INFLUENZA & COVID-19 MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 42 GLOBAL INFLUENZA & COVID-19 INDICATION MARKET 2021–2027 ($ MILLION)

EXHIBIT 43 GLOBAL HERPES SIMPLEX VIRUS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 44 GLOBAL HERPES SIMPLEX VIRUS INDICATION MARKET 2021–2027 ($ MILLION)

EXHIBIT 45 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 46 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET 2021–2027 ($ MILLION)

EXHIBIT 47 GLOBAL VARICELLA-ZOSTER VIRUS MARKET 2021–2027 ($ MILLION)

EXHIBIT 48 GLOBAL VARICELLA ZOSTER VIRUS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 49 GLOBAL OTHERS INDICATION MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 50 GLOBAL OTHER VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 51 INCREMENTAL GROWTH BY END-USER 2021 C& 2027

EXHIBIT 52 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2022-2027

EXHIBIT 53 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER: INCREMENTAL GROWTH

EXHIBIT 54 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER: ABSOLUTE GROWTH

EXHIBIT 55 GLOBAL LABS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 56 GLOBAL LABS VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 57 GLOBAL HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 58 GLOBAL HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 59 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY OTHER END-USERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH

EXHIBIT 60 GLOBAL OTHERS VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 61 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027

EXHIBIT 62 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2022-2027

EXHIBIT 63 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY: INCREMENTAL GROWTH

EXHIBIT 64 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY: ABSOLUTE GROWTH

EXHIBIT 65 VIRAL TRANSPORT MEDIUM MARKET NORTH AMERICA: KEY COUNTRIES 2019 ($ MILLION)

EXHIBIT 66 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 67 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 68 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027

EXHIBIT 69 US VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 70 CANADA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 71 VIRAL TRANSPORT MEDIUM MARKET EUROPE: KEY COUNTRIES 2019 ($ MILLION)

EXHIBIT 72 EUROPE VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 73 EUROPE VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 74 INCREMENTAL GROWTH IN EUROPE 2021 & 2027

EXHIBIT 75 UK: VARICELLA AGE-SPECIFIC ANNUAL COMMUNITY INCIDENTS PER 100,000

EXHIBIT 76 UK VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 77 FRANCE: AGE-SPECIFIC ANNUAL COMMUNITY INCIDENCE OF VARICELLA PER 100,000

EXHIBIT 78 FRANCE VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 79 ITALY: INCIDENCE OF HERPES BY AGE GROUP & GENDER

EXHIBIT 80 ITALY VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 81 GERMANY: TOTAL COVID-19 CASES AUG 2021–FEB 2022 (MILLION)

EXHIBIT 82 GERMANY VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 83 SPAIN VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 84 VIRAL TRANSPORT MEDIUM MARKET APAC: KEY COUNTRIES 2019 ($ MILLION)

EXHIBIT 85 APAC VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 86 APAC VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 87 INCREMENTAL GROWTH IN APAC 2021 & 2027

EXHIBIT 88 CHINA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 89 JAPAN VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 90 INDIA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 91 AGE STANDARDIZED HOSPITALIZATION RATE NOTIFIABLE COMMUNICATION DISEASES 2013–2017

EXHIBIT 92 AUSTRALIA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 93 SOUTH KOREA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 94 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET: KEY COUNTRIES 2019 ($ MILLION)

EXHIBIT 95 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 96 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 97 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027

EXHIBIT 98 PREVALENCE OF HERPES ZOSTER IN BRAZIL (VIA REGION) 2021

EXHIBIT 99 BRAZIL VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 100 MEXICO VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 101 ARGENTINA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 102 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET: KEY COUNTRIES 2019 ($ MILLION)

EXHIBIT 103 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET: INCREMENTAL & ABSOLUTE GROWTH

EXHIBIT 104 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 105 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027

EXHIBIT 106 TURKEY: INCIDENT RATE OF HERPES ZOSTER WITH RESPECT TO AGE (2011–2019) (PER 100,000 PEOPLE)

EXHIBIT 107 TURKEY VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 108 SAUDI ARABIA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 109 SOUTH AFRICA VIRAL TRANSPORT MEDIUM MARKET 2021–2027 ($ MILLION)

EXHIBIT 110 THERMO FISHER SCIENTIFIC: ANNUAL REVENUE 2018–2020 ($ BILLION)

EXHIBIT 111 THERMO FISHER SCIENTIFIC ANNUAL REVENUE BY SEGMENT 2020 (%)

LIST OF TABLES

TABLE 1 KEY CAVEATS

TABLE 2 CURRENCY CONVERSION 2015−2021

TABLE 3 SOME OF COVID-19 TRANSPORT MEDIA MANUFACTURER AND PRODUCTS

TABLE 4 COVID-19 TEST DONE DURING 2020-2022

TABLE 5 VIRAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 6 VIRAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 7 UNIVERSAL TRANSPORT MEDIA KIT & MANUFACTURER

TABLE 8 UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 9 UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 10 MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 11 MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 12 OVERALL COVID-19 DIAGNOSIS TEST BY REGION IN 2022

TABLE 13 VIRAL TRANSPORT MEDIUM DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 14 VIRAL TRANSPORT MEDIUM DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 15 VIRAL TRANSPORT MEDIUM PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 16 VIRAL TRANSPORT MEDIUM PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 17 VIRAL TRANSPORT MEDIUM INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 18 VIRAL TRANSPORT MEDIUM INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 19 VIRAL TRANSPORT MEDIUM HERPES SIMPLEX VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 20 VIRAL TRANSPORT MEDIUM HERPES SIMPLEX VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 21 VIRAL TRANSPORT MEDIUM RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 22 VIRAL TRANSPORT MEDIUM RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 23 VIRAL TRANSPORT MEDIUM VARICELLA-ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 24 VIRAL TRANSPORT MEDIUM VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 25 OTHER VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 26 OTHER VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 27 LABS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 28 LABS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 29 HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 30 HOSPITALS & CLINICS VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 31 OTHER VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 32 OTHER VIRAL TRANSPORT MEDIUM KITS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 33 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)

TABLE 34 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)

TABLE 35 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 36 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 37 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)

TABLE 38 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)

TABLE 39 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 40 NORTH AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)

TABLE 41 US: MEDICAL DIAGNOSTICS LABS

TABLE 42 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)

TABLE 43 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)

TABLE 44 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 45 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 46 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)

TABLE 47 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)

TABLE 48 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 49 EUROPE VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)

TABLE 50 APAC VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)

TABLE 51 APAC VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)

TABLE 52 APAC VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 53 APAC VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 54 APAC VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)

TABLE 55 APAC VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)

TABLE 56 APAC VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 57 APAC VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)

TABLE 58 CHINA: LABORATORY DETECTION OF ILI SPECIMENS WEEK 15 IN 2019.

TABLE 59 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)

TABLE 60 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)

TABLE 61 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 62 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 63 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)

TABLE 64 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)

TABLE 65 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 66 LATIN AMERICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)

TABLE 67 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2021−2027 ($ MILLION)

TABLE 68 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY PRODUCTS 2021−2027 (%)

TABLE 69 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 70 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 71 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)

TABLE 72 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)

TABLE 73 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 74 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 75 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 76 MIDDLE EAST & AFRICA VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)

TABLE 77 BD: MAJOR PRODUCT OFFERINGS

TABLE 78 HARDY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 79 HIMEDIA LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 80 LABORATORY CORPORATION OF AMERICA: MAJOR PRODUCT OFFERINGS

TABLE 81 PURITAN MEDICAL PRODUCTS: MAJOR PRODUCT OFFERINGS

TABLE 82 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 83 VIRCELL: MAJOR PRODUCT OFFERINGS

TABLE 84 AB MEDICAL: MAJOR PRODUCT OFFERINGS

TABLE 85 ACCUGENE USA: MAJOR PRODUCT OFFERINGS

TABLE 86 APICAL SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 87 AZOOKA LABS: MAJOR PRODUCT OFFERINGS

TABLE 88 BIOMED DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 89 BIOBOAVISTA: MAJOR PRODUCT OFFERINGS

TABLE 90 BIOGENEX LABORATORIES: MAJOR PRODUCT OFFERINGS

TABLE 91 BIOLOGIX GROUP: MAJOR PRODUCT OFFERINGS

TABLE 92 BIOCOMMA: MAJOR PRODUCT OFFERINGS

TABLE 93 CHARM SCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 94 CREATIVE LIFE SCIENCES CO. LTD.: MAJOR PRODUCT OFFERINGS

TABLE 95 CITOTEST LABWARE MANUFACTURING: MAJOR PRODUCT OFFERINGS

TABLE 96 CPT MEDICAL: MAJOR PRODUCT OFFERINGS

TABLE 97 COPAN DIAGNOSTIC INC.: MAJOR PRODUCT OFFERINGS

TABLE 98 DIASORIN MOLECULAR: MAJOR PRODUCT OFFERINGS

TABLE 99 EKF DIAGNOSTIC: MAJOR PRODUCT OFFERINGS

TABLE 100 ENSOL BIOSCIENCES: MAJOR PRODUCT OFFERINGS

TABLE 101 GEMINI BIOPRODUCTS: MAJOR PRODUCT OFFERINGS

TABLE 102 GENERAL BIOLOGICS: MAJOR PRODUCT OFFERINGS

TABLE 103 GENTUERI: MAJOR PRODUCT OFFERINGS

TABLE 104 GENESIS LIFETECH MARKETING: MAJOR PRODUCT OFFERINGS

TABLE 105 HAN CHANG MEDIC: MAJOR PRODUCT OFFERINGS

TABLE 106 HEBEI CHAORAN MEDICAL INSTRUMENTS: MAJOR PRODUCT OFFERINGS

TABLE 107 KSL DIAGNOSTICS: MAJOR PRODUCT OFFERINGS

TABLE 108 LUCENCE HEALTH: MAJOR PRODUCT OFFERINGS

TABLE 109 LAUNCHWORKS: MAJOR PRODUCT OFFERINGS

TABLE 110 LIOFILCHEM: MAJOR PRODUCT OFFERINGS

TABLE 111 MEDICAL WIRE & EQUIPMENT: MAJOR PRODUCT OFFERINGS

TABLE 112 MIRACLEAN TECHNOLOGY (MANTACC): MAJOR PRODUCT OFFERINGS

TABLE 113 METADESIGN SOLUTIONS: MAJOR PRODUCT OFFERINGS

TABLE 114 MANILA HEALTHTEK: MAJOR PRODUCT OFFERINGS

TABLE 115 MATTEK: MAJOR PRODUCT OFFERINGS

TABLE 116 NODFORD INTERNATIONAL: MAJOR PRODUCT OFFERINGS

TABLE 117 STARPLEX SCIENTIFIC: MAJOR PRODUCT OFFERINGS

TABLE 118 SANSURE BIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 119 TITAN BIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 120 VEGAS BIOTECH: MAJOR PRODUCT OFFERINGS

TABLE 121 ZYBIO: MAJOR PRODUCT OFFERINGS

TABLE 122 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 123 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 124 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 ($ MILLION)

TABLE 125 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY PRODUCT 2021−2027 (%)

TABLE 126 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 ($ MILLION)

TABLE 127 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY USAGE 2021−2027 (%)

TABLE 128 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 ($ MILLION)

TABLE 129 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY INDICATION 2021−2027 (%)

TABLE 130 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 ($ MILLION)

TABLE 131 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY END-USER 2021−2027 (%)

TABLE 132 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 133 GLOBAL VIRAL TRANSPORT MEDIUM MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 134 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 135 GLOBAL UNIVERSAL TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 136 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 137 GLOBAL MOLECULAR TRANSPORT MEDIA MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 138 GLOBAL DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 139 GLOBAL DIAGNOSIS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 140 GLOBAL PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 141 GLOBAL PRE-CLINICAL TESTING MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 142 GLOBAL INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 143 GLOBAL INFLUENZA & COVID-19 MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 144 GLOBAL HERPES MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 145 GLOBAL HERPES MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 146 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 147 GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 148 GLOBAL VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 149 GLOBAL VARICELLA ZOSTER VIRUS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 150 GLOBAL OTHER (INDICATIONS) MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 151 GLOBAL OTHER (INDICATIONS) MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 152 GLOBAL LABS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 153 GLOBAL LABS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 154 GLOBAL HOSPITALS & CLINICS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 155 GLOBAL HOSPITALS & CLINICS MARKET BY GEOGRAPHY 2021−2027 (%)

TABLE 156 GLOBAL OTHER INDICATION MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)

TABLE 157 GLOBAL OTHER INDICATION MARKET BY GEOGRAPHY 2021−2027 (%)

Select a license type that suits your business needs

single-user Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3995.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4995.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date